Decreased or altered expression of the FHIT gene in human leukemias

Stem Cells
K SugimotoK Oshimi

Abstract

The FHIT (fragile histidine triad) gene on chromosome 3p14 is a candidate tumor suppressor gene, and its transcripts are shown to be abnormal in several human cancers. We examined 40 leukemia samples for the alterations of FHIT transcripts by reverse transcriptase-polymerase chain reaction (RT-PCR) and direct sequencing. Intact FHIT mRNA was not detected in two patients with acute myeloid leukemia (AML) and in one patient with chronic lymphocytic leukemia (CLL). The three cases expressed only an aberrant FHIT mRNA lacking exons 3 to 6 (FHIT delta 3-6 mRNA), which could encode a polypeptide of 13 amino acids. Southern blot analysis on two samples from these cases showed no rearrangements of the FHIT gene. Although intact FHIT mRNA was detected as the main band in the remaining 37 samples, 33 of them (14 of 14 AML, 11 of 13 chronic myeloid leukemia, five of five acute lymphocytic leukemia, and three of five CLL) expressed aberrant FHIT delta 3-6 mRNA. We barely detected the FHIT delta 3-6 mRNA in only one of 25 normal control samples. Our results suggest that loss of the normal FHIT function may be involved in the genesis of at least some human leukemias and that expression of aberrant FHIT transcripts is rather specific and freq...Continue Reading

References

Oct 1, 1990·Molecular and Cellular Biology·J Cheng, M Haas
Apr 1, 1986·Proceedings of the National Academy of Sciences of the United States of America·J C Baker, M K Jacobson
Apr 1, 1993·Trends in Genetics : TIG·B Vogelstein, K W Kinzler
Apr 5, 1996·Cell·G SozziC M Croce

❮ Previous
Next ❯

Citations

Apr 12, 2002·Cancer Genetics and Cytogenetics·Giorgina SpecchiaVincenzo Liso
Feb 3, 1999·Annual Review of Genetics·K HuebnerC M Croce
Dec 25, 2009·Journal of Cancer Research and Clinical Oncology·Md Imtaiyaz HassanFaizan Ahmad
Jul 7, 2009·The Journal of Veterinary Medical Science·Hiroko HiraokaMasaru Okuda
Jun 11, 1999·International Journal of Cancer. Journal International Du Cancer·H W YangY Hayashi
Jan 8, 2014·Experimental and Therapeutic Medicine·Jiayun GeLin Wang

❮ Previous
Next ❯

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

B-Cell Leukemia (Keystone)

B-cell leukemia includes various types of lymphoid leukemia that affect B cells. Here is the latest research on B-cell leukemia.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.